


17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
<b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO <b>\$1000.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO <b>\$ 860.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO <b>\$ 710.00</b>  International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) <b>\$ 690.00</b>  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) <b>\$ 100.00</b>  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>					
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<b>\$ 130.00</b>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	<b>30 - 20 =</b>	<b>0</b>	<b>X \$18.00</b>	<b>\$ 180.00</b>	
Independent claims	<b>3 - 3 =</b>	<b>0</b>	<b>X \$78.00</b>	<b>\$ 0</b>	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			<b>+\$260.00</b>	<b>\$ 260.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$1570.00</b>	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				<b>\$</b>	
<b>SUBTOTAL =</b>				<b>\$</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). <b>+</b>				<b>\$</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property <b>+</b>				<b>\$</b>	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1570.00</b>	
				Amount to be:	\$
				refunded	
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of <b>\$1570.00</b> to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. <b>07-1969</b> in the amount of \$_____ to cover the above fees.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <b>07-1969</b> . A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO:					
GREENLEE, WINNER and SULLIVAN, P.C. 5370 Manhattan Circle, Suite 201 Boulder, CO 80303 Phone: 303-499-8080 Fax: 303-499-8089					
 SIGNATURE					
Name: Donna M. Ferber Registration No.: <b>33,878</b>					

13 Rec'd PCT/PTO 29 MAR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

09/936869

In re Application of:

Podila et al.

: Group Art Unit: Not yet assigned

Serial No: 09/936,869

: Examiner: Not yet assigned

International Application No. PCT/NZ00/00031

: Confirmation No. 9480

International Filing Date: March 17, 2000

For: PLANTS HAVING MODIFIED REPRODUCTIVE CAPACITY

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as EXPRESS MAIL in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.	
29 March 2002 Date	B. Kroge B. Kroge
Express Mail Receipt No: EL 827 990 328 US	

PRELIMINARY AMENDMENT

Commissioner for Patents  
Box PCT  
Washington, D.C. 20231

Sir:

Please enter the following amendments:

In the Specification:

**At page 1, after the title, please insert:**

This application was filed under 35 U.S.C. 371, based on PCT/NZ00/00031, which application was filed March 17, 2000 and claims priority from New Zealand Application No. 334715, filed March 17, 1999.

**At page 4, rewrite the paragraphs describing Figures 1 and 2 as follows:**

Figure 1 shows the amino acid sequence of the reproductive peptide PrAG1, together with the nucleotide sequence coding therefor (SEQ ID NO:3);

**09 JAN 68 09 00**

5' PCR primer: 5' AAYCGICARGTIACITT 3' (SEQ ID NO:8)

**Primer GSP2: 5' GAC CTG TCG GTT CGT AGT ATT TTC AAT CCT 3' (SEQ ID NO:10)**

**Primer GSP4: 5' GCA CTC CAC TCT TCC TTT ATT TCT TAC CAC 3' (SEQ ID NO:12)**

2







**Marked up version of amended claims and paragraphs in attached Amendment.**

Docket No.: 103-01  
 USSN 09/936,869  
 Filed: September 17, 2001

**At page 4, the paragraphs describing Figures 1 and 2:**

Figure 1 shows the amino acid sequence of the reproductive peptide PrAG1, together with the nucleotide sequence coding therefor (SEQ ID NO:3);

Figure 2 shows the sequence of the PrAG1 promoter, which is the focus of the present invention, isolated from *Pinus radiata* (SEQ ID NO:1);

**At page 14, the sequences beginning at line 28:**

3' PCR primer: 5' GCIGTIAGIYCITCICCCAT 3'; (SEQ ID NO:[6]7)  
 5' PCR primer: 5' AAYCGICARGTIACITT 3' (SEQ ID NO:[7]8)

**At page 16, the sequences beginning at line 31:**

Primer GSP1: 5' CGC CTT CTT CAA TAA ACC ATT TCG GCG CTT 3' (SEQ ID NO:[8]9)  
 Primer GSP2: 5' GAC CTG TCG GTT CGT AGT ATT TTC AAT CCT 3' (SEQ ID NO:[9]10)

**At page 17, lines 4 and 5:**

Primer GSP3: 5' TTC GTC CTC CAT TTT GTG CGC TCT CCA TTC 3' (SEQ ID NO:[10]11)  
 Primer GSP4: 5' GCA CTC CAC TCT TCC TTT ATT TCT TAC CAC 3' (SEQ ID NO:[11]12)

**At page 19, the paragraph beginning at line 18:**

Analysis was performed on total RNA isolated from needle, stem, vegetative shoot, immature female cone and immature male cone samples as described above. RNA was reverse-transcribed with MMLV reverse-transcriptase (Gibco BRL) according to the manufacturer's instructions. PCR was performed with two primers: 5'PCR primer (5' TTGTGTACAAATCATGGG 3') (SEQ ID NO:[13]14) and 3'PCR primer (5'GTAAGCCCGTCACCCATC 3') SEQ ID NO:[14]15). Verification of the specificity of the PCR reactions was achieved through the use of controls that

included amplification reaction with single primers, RNase treatment of template, and no template. In those reactions in which no PCR product was detected, the quality of the RNA was tested by UV scanning and agarose gel electrophoresis. ss-cDNA from the RTR reaction was used as a template. The 50- $\mu$ l reaction mixture contained 2.5 U Taq DNA [polymease] polymerase, 1X Polymerization Buffer (both from ClonTech Co.), 1mM MgCl<sub>2</sub>, 0.2mM dNTP and 0.25 $\mu$ M primers. The PCR was performed under following conditions: denaturation at 94°C for 30 s, annealing at 55°C for 1 min and extension at 72°C for 1 min for 30 cycles on Thermal Cycler 480 (Perkin-Elmer, Norwalk, CT, USA). The PCR products were subjected to electrophoresis in agarose gel, and hybridization as described above.

**At page 21, the paragraph beginning at line 7:**

To check the genomic DNA integration of pRAGPR in the transgenic tobacco plants, gene-specific primers for the NPTII gene were employed. The primers used were NPTII-5' primer 5-GAA CAA GAT GCA TTG CAC GC-3' (SEQ ID NO:[15]16) and NPTII-3' primer 5'-GAA GAA CTC GTC AAG AAG GC-3' (SEQ ID NO:[16]17). Genomic DNA from each of the control lines and transgenic tobacco lines were isolated from the leaf tissue using the Qiagen DNAeasy kit as per manufacturer's instructions. PCR reactions (50- $\mu$ l final volume) were performed using 5  $\mu$ l of template DNA. Samples were heated to 95°C for 4 minutes, followed by 35 cycles of 95°C for 45 seconds, 55°C for 30 seconds, and 73°C for 2 minutes, with a final extension step of 73°C for 5 minutes in PTC100 thermal cycler (MJ Research). Amplified DNA fragments were analyzed on a 0.8% agarose gel and visualized by staining with ethidium bromide.

**In the Claims:**

5. (Twice amended) A DNA construct which comprises:
  - (a) a promoter sequence [according to claim 2 or claim 3] as given in SEQ ID NO:1 or a functionally equivalent variant thereof which has at least 90% homology to SEQ ID NO:1 or as given in SEQ ID NO:2;
  - (b) an open reading frame polynucleotide coding for a peptide; and
  - (c) a termination sequence.







13 Rec'd PCT/PTO 29 MAR 2002

09/936869

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

:

Podila et al.

: Group Art Unit: Not yet assigned

Serial No: 09/936,869

: Examiner: Not yet assigned

International Application No. PCT/NZ00/00031

: Confirmation No. 9480

International Filing Date: March 17, 2000

For: PLANTS HAVING MODIFIED REPRODUCTIVE CAPACITY

STATEMENT UNDER 37 C.F.R. §1.821-824


Commissioner for Patents  
Box PCT  
Washington, D.C. 20231

Sir:

In response to the Notification of Missing Requirements under 35 USC 371, Applicants submit herewith a paper copy of Sequence Listing as pages 1 - 9 and a write-protected diskette copy of the Sequence Listing in computer-readable form as required by 37 C.F.R. §1.821(e).

In compliance with 37 C.F.R. §1.821(f), the undersigned states that the content of the paper copies and computer-readable copies of the Sequence Listing are the same.

Respectfully submitted,



Donna M. Ferber  
Reg. No. 33,878

GREENLEE, WINNER AND SULLIVAN, P.C.  
5370 Manhattan Circle, Suite 201  
Boulder, CO 80303  
Telephone (303) 499-8080  
Facsimile: (303) 499-8089  
Email: winner@greenwin.com

Attorney Docket No. 103-01  
bmk: March 29, 2002

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as EXPRESS MAIL in an envelope addressed to the Commissioner for Patents, Washington, D.C., 20231

29 March 2002

Date

B. Kroge

B. Kroge

Express Mail Receipt No.: EL 827 990 328 US

09/936869

256351.txt  
SEQUENCE LISTING

<110> Carter Holt Harvey Limited  
Fletcher Challenge Forests Limited  
Michigan Technological University  
Podila, Gopi Krishna  
Liu, Jun-Jun  
Karnosky, David F

<120> Plants Having Modified Reproductive Activity

<130> 25635 MRB

<140>

<141>

<150> NZ334715

<151> 1999-03-17

<160> 17

<170> PatentIn Ver. 2.1

<210> 1

<211> 1320

<212> DNA

<213> Pinus radiata

<400> 1

aaactcgaca	gcaaatatga	tttagattat	gacctagaaa	taagcatagc	attaaagcat	60
atacataaca	agcgggtgata	tactctgact	gccactgtac	ttgaggaaaag	gtagtggact	120
ctgctcaggt	acattagttt	ggtaagggtg	gcttggttc	tgggtaatat	gagaagtaaa	180
gaagtaaaaag	gtatttgact	ctagtcaagt	acattggatt	gcctttgtcg	gggcttggat	240
ggcttgggtt	cgtgtgagaa	gccaacaatt	tataagaaat	atataaaata	aaaaataaaa	300
aaattttaagt	gttggaaagt	aaaacggtgg	ggcagaaata	tacacagaag	agtactttta	360
caatgcgcaa	ccaaggcaga	ttcacaactt	gatttctgga	cctcgaatac	gagataatgg	420
tggtaagaaa	taaaggaaga	gtggagtgca	tttggaaaatg	aatggagagc	gcacaaaatg	480
gaggacgaat	aaatgaaata	taatgcaaga	gtgcatttcc	ctattatttc	cagaaatgta	540
tatgtgggggt	cggcattcac	atgggcgtcg	cattcagggg	gtgtcatagc	ggtcctttga	600
ttgcagtgtg	ggagtgtgca	catgtacca	caaatccatt	catcccaaaa	cctaaattta	660
tccctctccat	tactattacc	tacacctata	cctagtaaat	atgtcctgcc	ttgtaactcc	720
tccactgcct	gcacacgtct	tagtcaatcc	atctgccttc	aaataggcat	tattttgttc	780
tttccctctc	gactgaaagg	ctatcgaccg	accgaccgct	catcttcttc	ttctgcgcaa	840
ttttttctgc	tggatcatca	tcattaccat	catcgccatc	cccaccatca	tcatcatgat	900
ggtatctcta	tctctccctg	gcaatcgatt	gtagaggaaa	ggaagaggga	aggggcatat	960
gtattgatca	acctaccgga	aaaaacaatc	tgatcagccc	tgctcaatct	tgcttataaa	1020
tctcttatcc	actgttcaat	cattcagggtt	tcttcccact	ttcaagcaaa	ggcgcccggg	1080
ttggccgtgt	tcttagattt	tcagggtactt	aaatggacaa	tattccccac	ctgaagccgt	1140
tctgaaaaag	atttgtttgt	agaaacaaac	gattgtaata	tttgcttaag	ttgagcttaa	1200
gggggttggg	acctaacttg	ccttggtggt	atttgtttct	cagaactcgg	gctgcgtcca	1260
actgtaggaa	cgaaccagca	caaggggttg	cagcttttgc	tggtgctggt	gcgcccattg	1320

<210> 2

<211> 1401

<212> DNA

<213> Pinus radiata

<400> 2

aaactcgaca	gcaaatatga	tttagattat	gacctagaaa	taagcatagc	attaaagcat	60
atacataaca	agcgggtgata	tactctgact	gccactgtac	ttgaggaaaag	gtagtggact	120
ctgctcaggt	acattagttt	ggtaagggtg	gcttggttc	tgggtaatat	gagaagtaaa	180
gaagtaaaaag	gtatttgact	ctagtcaagt	acattggatt	gcctttgtcg	gggcttggat	240



256351.txt

Thr 65	Ile	Glu	Arg	Tyr	Lys 70	Lys	Thr	Cys	Val	Asp 75	Asn	Asn	His	Gly	Gly 80	
gcg Ala	ata Ile	tca Ser	gag Glu	tcc Ser 85	aat Asn	tct Ser	cag Gln	tat Tyr	tgg Trp 90	caa Gln	cag Gln	gag Glu	gct Ala	ggt Gly 95	aaa Lys	288
ctc Leu	aga Arg	caa Gln	cag Gln 100	att Ile	gac Asp	att Ile	ttg Leu	caa Gln 105	aat Asn	gca Ala	aat Asn	agg Arg	cat His 110	ttg Leu	atg Met	336
ggt Gly	gac Asp	ggg Gly 115	ctt Leu	aca Thr	gct Ala	ttg Leu	aac Asn 120	att Ile	aag Lys	gaa Glu	ctc Leu	aag Lys 125	caa Gln	ctt Leu	gag Glu	384
gtt Val	cga Arg 130	ctt Leu	gaa Glu	aaa Lys	gga Gly	atc Ile 135	agc Ser	cga Arg	gtg Val	cga Arg	tcc Ser 140	aaa Lys	aag Lys	aac Asn	gag Glu	432
atg Met 145	ttg Leu	ctt Leu	gaa Glu	gag Glu	atc Ile 150	gac Asp	atc Ile	atg Met	cag Gln	aga Arg 155	agg Arg	gaa Glu	cac His	ata Ile	ctt Leu 160	480
atc Ile	cag Gln	gag Glu	aat Asn	gag Glu 165	att Ile	ctt Leu	cgc Arg	agc Ser	aag Lys 170	ata Ile	gcc Ala	gag Glu	tgt Cys	cag Gln 175	aat Asn	528
agc Ser	cac His	aac Asn	acg Thr 180	aac Asn	atg Met	tta Leu	tca Ser	gct Ala 185	ccg Pro	gaa Glu	tat Tyr	gat Asp	gca Ala 190	ctg Leu	ccc Pro	576
gca Ala	ttc Phe	gac Asp 195	tct Ser	cga Arg	aat Asn	ttc Phe	cta Leu 200	cat His	gca Ala	aat Asn	cta Leu	atc Ile 205	gat Asp	gcg Ala	gcc Ala	624
cat His	cac His 210	tat Tyr	gca Ala	cat His	cag Gln	gaa Glu 215	caa Gln	aca Thr	acg Thr	ctt Leu	cag Gln 220	ctt Leu	ggc Gly	tga		669
acg	ttg	aagc	ggt	ggac	gct	taaa	act	caa	tca	agg	cacc	cgaaaa	aatat	gctag	taacc	729
ttg	aat	gaga	ttc	cag	atcg	aaat	att	tcg	agg	caag	agc	acaat	ggaag	agatag	ctcc	789
tag	tat	gaat	atg	gatt	tat	gat	atta	aaca	tat	gg	tttgt	cagc	tttaa	tatat	ctgtt	849
tga	aac	aaag	aata	caac	at	attag	ctagt	at	tttttt	ttgg	cgc	atg	ttat	cttt	ctgtt	909

```
<210> 4
<211> 222
<212> PRT
<213> Pinus radiata
```

<400> 4  
Met Gly Arg Gly Lys Ile Glu Ile Lys Arg Ile Glu Asn Thr Thr Asn  
1 5 10 15  
Arg Gln Val Thr Phe Cys Lys Arg Arg Asn Gly Leu Leu Lys Lys Ala  
20 25 30  
Tyr Glu Leu Ser Val Leu Cys Asp Ala Glu Val Ala Leu Ile Val Phe  
35 40 45  
Ser Ser Arg Gly Arg Leu Tyr Glu Phe Ala Asn His Ser Val Lys Arg  
50 55 60  
Thr Ile Glu Arg Tyr Lys Lys Thr Cys Val Asp Asn His Gly Gly  
Page 3

[illegible]

```
<210> 5
<211> 1012
<212> DNA
<213> Arabidopsis thaliana
```

```
<220>
<221> CDS
<222> (16)..(795)
<223> Arabidopsis thaliana ribonuclease (RNS2) mRNA,
complete cds
```

```

<300>
<301> Taylor, C B.
      Bariola, P A.
      delCardayre, S B.
      Raines, R T.
      Green, P J.
<302> RNS2: a senescence-associated RNase of Arabidopsis that
      diverged from the S-RNases before speciation
<303> Proc. Natl. Acad. Sci. U.S.A.
<304> 90
<305> 11
<306> 5118-5122
<307> 1993
<308> Genbank
<309> 1994-10-30
<313> 1 TO 1012

```

<400>	5																51
atcgaattaa	agtc	atg	gcg	tca	cgt	tta	tgt	ctt	ctc	ctt	ctc	ggt	gcg				
		Met	Ala	Ser	Arg	Leu	Cys	Leu	Leu	Leu	Leu	Val	Ala				
		1				5					10						
tgt	atc	gcc	gga	gca	ttt	gcc	gga	gac	gtc	atc	gaa	ctc	aat	cga	tct	99	
Cys	Ile	Ala	Gly	Ala	Phe	Ala	Gly	Asp	Val	Ile	Glu	Leu	Asn	Arg	Ser		
		15					20					25					
cag	agg	gag	ttc	gat	tat	ttc	gct	cta	tct	ctt	caa	tgg	cct	gga	acc	147	
Gln	Arg	Glu	Phe	Asp	Tyr	Phe	Ala	Leu	Ser	Leu	Gln	Trp	Pro	Gly	Thr		
	30					35					40						

tat	tgc	cgt	gga	act	cgc	cat	tgt	tgc	tcc	aaa	aac	gct	tgc	tgc	aga	195
Tyr	Cys	Arg	Gly	Thr	Arg	His	Cys	Cys	Ser	Lys	Asn	Ala	Cys	Cys	Arg	
45					50					55					60	
ggc	tcc	gat	gct	cca	act	caa	ttc	aca	att	cat	ggg	tta	tgg	cct	gac	243
Gly	Ser	Asp	Ala	Pro	Thr	Gln	Phe	Thr	Ile	His	Gly	Leu	Trp	Pro	Asp	
				65					70					75		
tat	aac	gat	ggt	tcg	tgg	cct	tca	tgt	tgt	tat	cga	tct	gac	ttt	aaa	291
Tyr	Asn	Asp	Gly	Ser	Trp	Pro	Ser	Cys	Cys	Tyr	Arg	Ser	Asp	Phe	Lys	
			80					85					90			
gag	aag	gag	att	tca	acg	ttg	atg	gat	ggt	ctt	gag	aag	tac	tgg	cct	339
Glu	Lys	Glu	Ile	Ser	Thr	Leu	Met	Asp	Gly	Leu	Glu	Lys	Tyr	Trp	Pro	
		95					100					105				
agt	ctc	agt	tgt	ggt	tct	cca	tca	tca	tgc	aat	ggt	ggg	aaa	ggg	tca	387
Ser	Leu	Ser	Cys	Gly	Ser	Pro	Ser	Ser	Cys	Asn	Gly	Gly	Lys	Gly	Ser	
	110					115					120					
ttt	tgg	ggc	cac	gag	tgg	gag	aaa	cat	ggg	act	tgt	tct	tct	cct	gtt	435
Phe	Trp	Gly	His	Glu	Trp	Glu	Lys	His	Gly	Thr	Cys	Ser	Ser	Pro	Val	
125					130					135					140	
ttt	cat	gat	gag	tat	aat	tac	ttc	ctt	acc	aca	ctt	aat	ctc	tac	ttg	483
Phe	His	Asp	Glu	Tyr	Asn	Tyr	Phe	Leu	Thr	Thr	Leu	Asn	Leu	Tyr	Leu	
				145					150					155		
aag	cat	aat	gtc	acg	gat	gtc	ctt	tat	caa	gct	ggc	tat	gtt	gct	tcc	531
Lys	His	Asn	Val	Thr	Asp	Val	Leu	Tyr	Gln	Ala	Gly	Tyr	Val	Ala	Ser	
			160					165					170			
aac	agt	gaa	aag	tat	cct	cta	gga	ggt	atc	gta	aca	gcc	att	cag	aat	579
Asn	Ser	Glu	Lys	Tyr	Pro	Leu	Gly	Gly	Ile	Val	Thr	Ala	Ile	Gln	Asn	
		175					180					185				
gca	ttt	cat	atc	acc	cct	gaa	gtg	gtt	tgc	aaa	aga	gat	gca	atc	gat	627
Ala	Phe	His	Ile	Thr	Pro	Glu	Val	Val	Cys	Lys	Arg	Asp	Ala	Ile	Asp	
						195					200					
gaa	ata	cgt	ata	tgc	ttc	tat	aaa	gat	ttt	aag	ccc	agg	gac	tgt	gtt	675
Glu	Ile	Arg	Ile	Cys	Phe	Tyr	Lys	Asp	Phe	Lys	Pro	Arg	Asp	Cys	Val	
205					210					215					220	
ggt	tca	caa	gat	ttg	aca	tct	aga	aag	tca	tgc	ccc	aag	tac	gta	agt	723
Gly	Ser	Gln	Asp	Leu	Thr	Ser	Arg	Lys	Ser	Cys	Pro	Lys	Tyr	Val	Ser	
				225					230					235		
ttg	ccg	gaa	tac	acg	cca	tta	gat	ggt	gaa	gct	atg	gtt	ctg	aag	atg	771
Leu	Pro	Glu	Tyr	Thr	Pro	Leu	Asp	Gly	Glu	Ala	Met	Val	Leu	Lys	Met	
			240					245								





<221> modified\_base  
<222> (9)  
<223> n=i

<220>  
<221> modified\_base  
<222> (12)  
<223> n=i

<220>  
<221> modified\_base  
<222> (15)  
<223> n=i

<400> 7  
gcngtnagny cntcncccat

20

<210> 8  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Made in lab

<220>  
<221> modified\_base  
<222> (6)  
<223> n=i

<220>  
<221> modified\_base  
<222> (12)  
<223> n=i

<220>  
<221> modified\_base  
<222> (15)  
<223> n=i

<400> 8  
aaycgncarg tnacntt

17

<210> 9  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Made in lab

<400> 9  
cgcccttcttc aataaaccat ttcggcgctt

30

<210> 10  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>

256351.txt

<223> Description of Artificial Sequence:Made in lab

<400> 10  
gacctgtcgg ttcgtagtat tttcaatcct 30

<210> 11  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Made in lab

<400> 11  
ttcgtcctcc attttgtgcg ctctccattc 30

<210> 12  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Made in lab

<400> 12  
gcactccact cttcctttat ttcttaccac 30

<210> 13  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Made in lab

<400> 13  
agttacttaa caatgcgcaa ccaaggc 27

<210> 14  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Made in lab

<400> 14  
ttgtgtacaa atcatggg 18

<210> 15  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Made in lab

<400> 15

256351.txt

```
<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence
```

<220>  
<223> Description of Artificial Sequence:Made in lab

<400> 16  
gaacaagatg gattgcacgc 20

<210>	17
<211>	20
<212>	DNA
<213>	Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Made in lab

```
<400> 17
gaagaactcg tcaagaaggc                20
```

**PLANTS HAVING MODIFIED REPRODUCTIVE CAPACITY**

This invention relates to plants having modified reproductive capacity. In particular, it relates to a plant reproductive tissue specific promoter and its use in promoting transcription/expression of associated genes in plant reproductive tissue, including for the purpose of producing plants which have diminished reproductive capacity or which are sterile.

**INTRODUCTION**

It is desirable that the genetic basis of reproduction/flower development in plants be determined. Identification of genes involved in plant reproduction and/or flower development together with the regulatory elements which control their expression in reproductive tissue allows for modulation of the reproductive capacity of plants and specifically enables the production of reproductively null (sterile) plants. Identification of the regulatory elements involved further allows for the expression in reproductive tissue of genes which are heterologous to the plant where that is desirable.

The applicants have now identified and isolated such a reproductive tissue specific promoter which endogenously regulates expression of a peptide involved in the reproductive cycle of *Pinus radiata*. It is broadly towards this promoter, to its homologs in other plants and to its use in effecting expression of associated genes within the reproductive tissue of plants that the present invention is directed.

**SUMMARY OF THE INVENTION**

In a first aspect, the present invention provides a polynucleotide which has a nucleotide sequence of from nucleotides 1 to 1320 of Figure 2 and which has the ability, when operatively associated with a nucleotide sequence encoding a peptide, to promote transcription of that nucleotide sequence, or a polynucleotide which is a functionally equivalent variant thereof.

In a second aspect, the invention provides a plant reproductive tissue promoter which has a nucleotide sequence of from nucleotides 1 to 1320 of Figure 2, or a functionally equivalent variant thereof.

5 In a further aspect, the invention provides a DNA construct which comprises:

- (a) a polynucleotide having activity as a transcriptional promoter as described above;
- (b) an open reading frame polynucleotide coding for a peptide; and
- 10 (c) a termination sequence.

In yet a further aspect, the invention provides a DNA construct which comprises:

- (a) a promoter sequence as defined above;
- 15 (b) an open reading frame polynucleotide coding for a peptide; and
- (c) a termination sequence.

In each construct the open reading frame can be in a sense orientation, or an anti-sense orientation.

20

In one embodiment, the open reading frame polynucleotide encodes a peptide having the sequence of Figure 1.

In other embodiments, the open reading frame polynucleotide encodes a peptide which, when expressed in reproductive tissue of a plant, causes said plant's reproductive organs to abort, to redefine themselves as vegetative, or to stop development.

25 In still another embodiment, the open reading frame polynucleotide encodes a peptide which, when expressed in the reproductive tissue of a plant, causes cell death.

30

In yet another embodiment, the open reading frame polynucleotide encodes a peptide, which when expressed in reproductive tissue of a flowering plant, causes an alteration in the timing of flowering of said plant.

5 In a preferred form, the construct further includes:

(d) a selection marker sequence.

10 In a further aspect, the invention provides a transgenic plant cell which includes a construct as described above.

By "transgenic" as used herein, the applicants mean containing non-endogenous genetic material.

15 In another aspect, the invention provides a transgenic plant which includes a construct as described above.

20 In still another aspect, the invention provides a transgenic plant which contains a polynucleotide having activity as a transcriptional promoter as described above or a reproductive tissue promoter as described above, which plant has a reduced reproductive capacity.

It is particularly preferred that the plant be sterile.

25 Conveniently, in said plant said polynucleotide or promoter is operatively associated with a nucleotide sequence encoding a RNase.

The plant can be a coniferous plant, such as a coniferous plant of the *Pinus* genus, or a tree such as a member of the *Eucalyptus* genus.

30

It is particularly preferred that the transgenic plant be a member of a species selected from *Pinus radiata*, *Pinus taeda*, *Pinus elliotti*, *Pinus clausa*, *Pinus palustris*, *Pinus echinata*, *Pinus ponderosa*, *Pinus jeffrey*, *Pinus resinosa*, *Pinus rigida*, *Pinus banksiana*, *Pinus serotina*, *Pinus strobus*, *Pinus monticola*, *Pinus lambertiana*, *Pinus*

*virginiana*, *Pinus contorta*, *Pinus cariboea*, *Pinus pinaster*, *Pinus brutia*, *Pinus eldarica*, *Pinus coulteri*, *Pinus nigra*, *Pinus sylvestris*, *Pinus tecunumannii*, *Pinus keysia*, *Pinus oocarpa* and *Pinus maximowii*.

## 5 DESCRIPTION OF THE DRAWINGS

While the invention is broadly as defined above, it will be appreciated by those persons skilled in the art that it is not limited thereto and that it further includes embodiments of which the following description provides examples. In addition, the invention will be better understood through reference to the accompanying drawings in which:

Figure 1 shows the amino acid sequence of the reproductive peptide PrAG1, together with the nucleotide sequence coding therefor;

Figure 2 shows the sequence of the PrAG1 promoter, which is the focus of the present invention, isolated from *Pinus radiata*;

Figure 3 is an RNA gel blot analysis of PrAG1 mRNA accumulation in *Pinus radiata* organs. Twenty µg of total RNA from various organs was electrophoresed, blotted onto nylon membranes, and hybridized with 3'-terminal fragment of PrAG1 cDNA. Total RNA was isolated from immature male cone(M), immature female cone(F), vegetative shoot (V)s, needle (N) and stem (S). The 26S and 18S rRNA was used as control (bottom);

Figure 4 is a DNA gel blot analysis of *Pinus radiata* genomic DNA hybridized with the 3' terminal region of PrAG1. 20 µg genomic DNA was digested with BamHI (BA) and Bgl II (BG) EcoRI(E), HindIII (H), XhoI(X);

Figure 5 is a Reverse Transcription-Polymerase Chain Reaction (RT-PCR) analysis showing reproductive-organ specific expression of PrAG1. RT-PCR analysis was performed on total RNA isolated from different organs of radiata Pine: (M) immature male cone, (F) immature female cone, (Vs) vegetative shoot, (N) needle and (S) stem. mads box genes were amplified with PrAG1 gene-specific oligonucleotides. Products



from the PCR reactions were electrophoresed, blotted, and hybridized with a labelled probe of PrAG1 specific fragment;

Figure 6 shows the construction of pRAGPR;

5

Figure 7. PCR analysis of transgenic tobacco lines. Genomic DNA (200 ng each) from controls and putative transgenic tobacco plants was used as template along with primers for NPTII gene. Lane PC is positive control (20 ng pRAGPR plasmid was used as a template); C1-C3 are control nontransformed tobacco plants; lanes 10 1a, 1b, 2, 3a, 3b, 3c, 4a, 4b are transgenic plants. The size of NPT II gene PCR product is indicated on the right;

Figure 8. Southern analysis of transgenic and control tobacco lines to confirm integration of PrAG1promoter-RNase gene cassette. Genomic DNA (20 ug each) was 15 digested with Hind III and Sac I enzymes, electrophoresed and transferred to a nylon membrane. <sup>32</sup>-P labeled RNase gene was used as a probe. The size of PrAG1promoter-RNase gene cassette is indicated on the right. Designation of control and transgenic plants is as indicated in Figure 7; and

20 Figure 9. Southern analysis of transgenic and control tobacco lines to confirm integration profiles of PrAG1promoter-RNase gene cassette. Genomic DNA (20 ug each) was digested with Hind III enzyme, electrophoresed and transferred to a nylon membrane. <sup>32</sup>-P labeled RNase gene was used as a probe. Sizes of DNA fragments hybridizing to the RNase gene probe are indicated on the right. Designation of 25 control and transgenic plants is as indicated in Figure 7.

## DESCRIPTION OF THE INVENTION

30 As broadly outlined above, the applicants have identified a plant promoter which is involved in plant reproduction. The promoter, which was isolated from *Pinus radiata* is called herein the "PrAG1 promoter".

The nucleotide sequence of the PrAG1 promoter is given in Figure 2 from 35 nucleotides 1 to 1320. It will however be appreciated that the invention is not

restricted only to the polynucleotide having that specific nucleotide sequence. Instead, the invention also extends to functionally equivalent variants of that polynucleotide.

- 5 The phrase "functionally equivalent variants" recognises that it is possible to vary nucleotide sequence while retaining substantially equivalent functionality.

Variants can have a greater or lesser degree of homology as between the variant nucleotide sequence and the original.

10

- Polynucleotide sequences may be aligned, and percentage of identical nucleotides in a specified region may be determined against another sequence, using computer algorithms that are publicly available. Two exemplary algorithms for aligning and identifying the similarity of polynucleotide sequences are the BLASTN and FASTA algorithms. The BLASTN software are available on the NCBI anonymous FTP server (ftp://ncbi.nlm.nih.gov) under /blast/executables/. The BLASTN algorithm version 2.0.4 [Feb-24-1998], set to the default parameters described in the documentation of variants according to the present invention. The use of the BLAST family of algorithms, including BLASTN, is described at NCBI's website at URL <http://www.ncbi.nlm.nih.gov/BLAST/newblast.html>. The computer algorithm FASTA is available on the Internet at the ftp site <ftp://ftp.virginia.edu/pub/fasta/>. Version 2.0u4, February 1996, set to the default parameters described in the documentation and distributed with the algorithm, is also preferred for use in the determination of variants according to the present invention. The use of the FASTA algorithm is described in W. R. Pearson and D. J. Lipman, "Improved Tools for Biological Sequence Analysis", *Proc. Natl. Acad. Sci. USA* 85:2444-2448 (1988).
- 15
- 20
- 25

- The following running parameters are preferred for determination of alignments and similarities using BLASTN that contribute to E values (as discussed below) and percentage identity: Unix running command: blastall -p blastn -d embldb -e 10 -G 1 -E 1 -r 2 -v 50 -b 50 -I queryseq -o results; and parameter default values:
- p Program Name [String]
  - d Database [String]
  - e Expectation value (E) [Real]
- 30

- G Cost to open a gap (zero invokes default behaviour) [Integer]
- E Cost to extend a gap (zero invokes default behaviour) [Integer]
- r Reward for a nucleotide match (blastn only) [Integer]
- v Number of one-line descriptions (V) [Integer]
- 5 -b Number of alignments to show (B) [Integer]
- i Query File [File In]
- o BLAST report Output File [File Out] Optional

10 The "hits" to one or more database sequences by a queried sequence produced by BLASTN, FASTA, or a similar algorithm, align and identify similar portions of sequences. The hits are arranged in order of the degree of similarity and the length of sequence overlap. Hits to a database sequence generally represent an overlap over only a fraction of the sequence length of the queried sequence.

15 The BLASTN and FASTA algorithms also produce "Expect" or E values for alignments. The E value indicates the number of hits one can "expect" to see over a certain number of contiguous sequences by chance when searching a database of a certain size. The Expect value is used as a significance threshold for determining whether the hit to a database, such as the preferred EMBL database, indicates true  
20 similarity. For example, an E value of 0.1 assigned to a hit is interpreted as meaning that in a database of the size of the EMBL database, one might expect to see 0.1 matches over the aligned portion of the sequence with a similar score simply by chance. By this criterion, the aligned and matched portions of the sequences then have a 90% probability of being the same. For sequences having an E value of  
25 0.01 or less over aligned and matched portions, the probability of finding a match by chance in the EMBL database is 1% or less using the BLASTN or FASTA algorithm.

30 It is also recognised that as the function of the polynucleotide is as a transcriptional promoter there are regions of the polynucleotide which are more critical to, and characteristic of, this function than others. An example are the TATA boxes at positions 280 to 286, 282 to 288 and 1015 to 1021 from the 5' end of the sequence. Therefore, polynucleotides which include these regions of the polynucleotide of Figure 2 and have equivalent transcriptional functionality are contemplated

variants, even where there is a lesser degree of homology elsewhere in the sequence.

According to one embodiment, "variant" polynucleotides, with reference to the  
5 polynucleotide of the present invention, preferably comprise sequences having the  
same number or fewer nucleic acids than the polynucleotide of the present  
invention and producing an E value of 0.01 or less when compared to the  
polynucleotide of the present invention. That is, a variant polynucleotide is any  
10 sequence that has at least a 99% probability of being the same as the  
polynucleotide of the present invention, measured as having an E value of 0.01 or  
less using the BLASTN or FASTA algorithms set at the parameters discussed above.

Variant polynucleotide sequences will also generally hybridize to the recited  
polynucleotide sequence under stringent conditions. As used herein, "stringent  
15 conditions" refers to prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at  
65°C, 6X SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in  
1X SSC, 0.1% SDS at 65°C and two washes of 30 minutes each in 0.2X SSC, 0.1%  
SDS at 65°C.

20 It is of course expressly contemplated that homologs to the PrAG1 promoter exist in  
other plants, particularly other coniferous plants, including other members of the  
*Pinus* genus. Such homologs are also "functionally equivalent variants" of PrAG1  
promoter as the phrase is used herein.

25 DNA sequences from plants other than *Pinus radiata* which are homologs of the  
PrAG1 promoter may be isolated by high throughput sequencing of cDNA libraries  
prepared from such plants. Alternatively, oligonucleotide probes based on the  
sequence for the PrAG1 promoter provided in Figure 2 can be synthesized and used  
to identify positive clones in either cDNA or genomic DNA libraries from other plants  
30 by means of hybridization or PCR techniques. Probes should be at least about 10,  
preferably at least about 15 and most preferably at least about 20 nucleotides in  
length. Hybridization and PCR techniques suitable for use with such  
oligonucleotide probes are well known in the art. Positive clones may be analyzed  
by restriction enzyme digestion, DNA sequencing or the like.



by transcription of the anti-sense oriented gene is complementary to all or part of the endogenous target mRNA.

Such anti-sense strategies are described generally by Robinson-Benion *et al.*,  
5 (1995), Anti-sense techniques, *Methods in Enzymol.* 254(23):363-375 and Kawasaki  
*et al.*, (1996), *Artific. Organs* 20 (8): 836-848.

Dominant negative approaches involve using the PrAG1 promoter to effect the  
expression of a modified DNA binding/activating protein which includes a DNA  
10 binding domain but not a activator domain. The result is that the protein binds to  
DNA as intended but fails to activate, while at the same time blocking the binding of  
the DNA binding/activating peptides which normally bind to the same site.

It is however presently preferred that the reproductive capacity of the plant be  
15 reduced or eliminated through the use of the PrAG1 promoter to drive transcription  
and expression of a nucleotide sequence which encodes an RNase within the plant  
reproductive tissue. Such an approach, in which the PrAG1 promoter is coupled to  
the RNase, RNS2, is exemplified herein.

20 To give effect to the above strategies, the invention also provides DNA constructs.  
The constructs include the PrAG1 promoter sequence, the DNA intended to be  
transcribed/expressed (such as the PrAG1 gene in sense or in anti-sense  
orientation or a polynucleotide encoding an RNase) and a termination sequence,  
operably linked to the DNA sequence to be transcribed. The promoter sequence is  
25 generally positioned at the 5' end of the DNA sequence to be transcribed, and is  
employed to initiate transcription of the DNA sequence.

The DNA with which the PrAG1 promoter is operatively associated can encode any  
peptide it is desirable to express in plant reproductive tissue. As indicated above,  
30 this includes the peptide encoded by PrAG1, but can also be another peptide. That  
other peptide can be a peptide which, when produced, causes the reproductive  
organs of the plant to abort, redefine themselves as vegetative or stop development.  
The peptide encoded can, for example, also be a peptide causing cell death.  
Illustrative peptides/genes are Diphtheria Toxin A (DTA), Barnase (from *Bacillus*



(*Molecular Cloning: A Laboratory Manual*, Cold Spring Harbour Laboratories, Cold Spring Harbour, NY, 1989). The DNA construct may be linked to a vector having at least one replication system, for example, *E. coli*, whereby after each manipulation, the resulting construct can be cloned and sequenced and the correctness of the manipulation determined.

The DNA constructs of the present invention may be used to transform a variety of plants. In one embodiment, these will be plants of the *Pinus* genus. In a preferred embodiment, the DNA constructs are employed to transform *Pinus radiata*, *Pinus taeda*, *Pinus elliotti*, *Pinus clausa*, *Pinus palustris*, *Pinus echinata*, *Pinus ponderosa*, *Pinus jeffrey*, *Pinus resinosa*, *Pinus rigida*, *Pinus banksiana*, *Pinus serotina*, *Pinus strobus*, *Pinus monticola*, *Pinus lambertiana*, *Pinus virginiana*, *Pinus contorta*, *Pinus cariboea*, *Pinus pinaster*, *Pinus brutia*, *Pinus eldarica*, *Pinus coulteri*, *Pinus nigra*, *Pinus sylvestris*, *Pinus tecunumannii*, *Pinus keyisia*, *Pinus oocarpa* and *Pinus maximowii*, and hybrids between the above species.

The constructs can also be used to transform other plants such as trees selected from *Abies amabilis*, *Abies balsamea*, *Abies concolor*, *Abies grandis*, *Abies lasiocarpa*, *Abies magnifica*, *Abies procera*, *Chamaecyparis lawsoniana*, *Chamaecyparis nootkatensis*, *Chamaecyparis thyoides*, *Huniperus virginiana*, *Larix decidua*, *Larix laricina*, *Larix leptolepis*, *Larix occidentalis*, *Larix siberica*, *Libocedrus decurrens*, *Picea abies*, *Picea engelmannii*, *Picea glauca*, *Picea mariana*, *Picea pungens*, *Picea rubens*, *Picea sitchensis*, *Pseudotsuga menziesii*, *Sequoia gigantea*, *Sequoiasempervirens*, *Taxodium distichum*, *Tsuga canadensis*, *Tsuga heterophylla*, *Tsuga mertensiana*, *Thuja occidentalis*, *Thuja plicata*; Eucalypts, such as *Eucalyptus alba*, *Eucalyptus bancroftii*, *Eucalyptus botyroides*, *Eucalyptus bridgesiana*, *Eucalyptus calophylla*, *Eucalyptus camaldulensis*, *Eucalyptus citriodora*, *Eucalyptus cladocalyx*, *Eucalyptus coccifera*, *Eucalyptus curtisii*, *Eucalyptus dalrympleana*, *Eucalyptus deglupta*, *Eucalyptus delagatensis*, *Eucalyptus diversicolor*, *Eucalyptus dunnei*, *Eucalyptus ficifolia*, *Eucalyptus globulus*, *Eucalyptus gomphocephala*, *Eucalyptus gunnii*, *Eucalyptus henryi*, *Eucalyptus laevopinea*, *Eucalyptus macarthurii*, *Eucalyptus macrorhyncha*, *Eucalyptus maculata*, *Eucalyptus marginata*, *Eucalyptus megacarpa*, *Eucalyptus melliodora*, *Eucalyptus nicholii*, *Eucalyptus nitens*, *Eucalyptus nova-anglica*, *Eucalyptus obliqua*, *Eucalyptus obtusiflora*, *Eucalyptus oreades*, *Eucalyptus pauciflora*, *Eucalyptus polybractea*, *Eucalyptus regnans*, *Eucalyptus resinifera*,







ClonTech Co.), 1mMMgCl<sub>2</sub> , 0.2mMdNTP and 0.25uM primers. The PCR was performed under the following conditions: denaturation at 94°C for 30 s, annealing at 50°C for 1 min and extension at 72°C for 1 min for 30 cycles on a Thermal Cycler 480 (Perkin-Elmer, Norwalk, CT, USA).

5

Fragments were obtained mostly from immature female bud tissue RNA samples. Several DNA fragments were cloned into pGEM-T vector and sequenced. Sequence analysis showed that most of these fragments contained similar sequences. One of the DNA fragments (309 bp) was chosen. This was used as a probe to screen the cDNA library to clone its full-length cDNA and resulted in the cDNA clone, PrAG1. The sequence of PrAG1 was analysed on both strands by the Sanger's dideoxy method (Sanger *et al.*, 1977, Proc. Natl. Acad. Sci. U.S.A. 74: using a Sequenase kit (United States Biochemical co.).

10

The resulting sequence is shown in Figure 1 gives the nucleotide sequence coding for the peptide of the invention together with the predicted amino acid sequence.

15

Sequence comparison and phylogenetic analysis were conducted with the software program MacDNASIS (Version 3.5, Hitachi Corp.). The results of analysis revealed PrAG1 to be a MADS box gene.

20

## **2. PrAG1 Promoter Cloning:**

### **I. Genomic DNA purification:**

25

Genomic DNA was purified from young needles according to a CTAB method as described below.

30

1) 2 g of young needles of *Pinus radiata* were ground in liquid nitrogen (mortar and pestle) to a fine powder.

2) This powder was mixed with 15 mL of pre-warmed CTAB extraction buffer [3% CTAB(W/V), 100mM Tris-HCl pH8.0, 20 mM EDTA pH8.0, 1.4 M NaCl, 1% PVP 940,000, 1% beta mercaptoethanol] and incubated at 65°C for one hour.



2) Based upon the promoter sequence we got from step 1), two PrAG1 promoter sequence specific primer were designed and synthesized. The primers were:

Primer GSP3: 5' TTC GTC CTC CAT TTT GTG CGC TCT CCA TTC 3' SEQ ID NO. 10

5 Primer GSP4: 5' GCA CTC CAC TCT TCC TTT ATT TCT TAC CAC 3'. SEQ ID NO. 11

3) According to the User Manual of Universal Genome Walker Kit, 13 genome walker libraries were constructed after genomic DNA digestion with restriction enzymes: EcoR V, Sca I, Dra I, Pvu II, Ssp I, Stu I, Sma I, Hap I, BsaB I, Bcl136 II, Pml I, Nru I, Hic II.

4) With 13 genome walker libraries as templates, and adaptor primer 1 (AP1 primer from kit) and GSP1 primer, first round PCR was performed under the conditions suggested by the kit manufacturer. After agarose electrophoresis analysis of the PCR product, second round PCR was performed with the nested primers AP2 (Adaptor primer from the kit) and GSP2. The PCR products from the second round PCR were purified and cloned into pGEM-T easy vector (Promega). Following sequence analysis, and DNA sequence comparison with PrAG1 cDNA, one DNA fragment of 1105 bp from Sca I genome walker library was obtained which was identified as the promoter region of PrAG1, based upon the overlapped region between it and PrAG1 cDNA.

5) The second step genome walking was done with primer pair AP1 and GSP3, and primer pair AP2 and GSG4. A DNA fragment of 449 bp from the Dra I genome walker library was identified as the upstream sequence of the PrAG1 promoter cloned from the first step genome walking based on the sequence comparison of overlapped region between them.

6) The 1105bp and 449 bp fragments were used in PCR mediated DNA splicing to synthesize one continuous 1458 bp promoter fragment of PrAG1. This was done as described. One primer was synthesized based on the 5'end sequence of 1105 bp promoter fragment: Primer PLi, 5' AGT TAC TTA ACA ATG CGC AAC CAA GGC 3' (SEQ ID NO. 12). Primer pair PLi and GSP2 was used in PCR to get the promoter fragment of 1105 bp, in which the AP2 primer sequence was removed. This 1105 bp

fragment and 449 bp fragment was then added in one PCR tube as a template with the primer pair of AP2 and GAP2 to do the second round PCR to get the 1458 bp PCR fragment. The conditions of second round PCR were as follows: the first cycle at 95°C for 5 minutes, and 68°C for 10 min; the second cycle at 94°C for 30 seconds (DNA denaturing), DNA annealing at 60 C for 1 min, and DNA synthesis at 72 C for 2 minutes; this regime was cycled 30 times. This 1458 bp fragment was then cloned into pGEM-T easy vector (Promega) and subjected to DNA sequencing on both strands to confirm the DNA sequence and to make sure that no base changes occurred during the PCR process.

The sequence of the promoter, (which is the PrAG1 promoter), is given in Figure 2 from nucleotides 1 to 1320.

7) DNA sequence analysis has indicated that compared to its orthologs from other plants, the PrAG1 showed that there were two possible positions for transcription initiation: at position 791 or 1326 in the Figure 2 sequence. It was found three typical TATA boxes in the PrAG1 promoter at the position of 280 to 286, 282 to 288, 1015 to 1021. Based on the start codon position and short 5' untranslated region in the PrAG1 cDNA, the transcription initiation point is identified as position 1326 in the Figure 2 sequence.

### **3. DNA and RNA Gel Blot Hybridizations:**

Genomic DNA and RNA gel blots were made using standard techniques (Sambrook et al., 1989. Molecular Cloning : A Laboratory Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press).

**RNA:** Total RNA was prepared from needle, vegetative shoot, stem, immature female cone and immature male cone samples as described above. Briefly, 20µg of total RNA was denatured in formaldehyde loading buffer and fractionated by denaturing agarose gel electrophoresis on a formaldehyde containing gel. The agarose gel was stained with ethidium bromide and a picture taken as control. The RNA was then transferred to a nylon membrane by the capillary blotting method. The RNA was immobilised on the membrane by UV cross-linking and was prehybridized at 65°C



The results are shown in Figure 5.

## Discussion

5

Northern blot hybridization and RT-PCR analysis showed that PrAG1 mRNA is accumulated specifically in the immature female cone and immature male cone; there is no expression detected in needle, stem, and vegetative shoot (Figures 3 and 5). This tissue distribution profile, when combined with the fact that PrAG1  
10 contains a MADS box, verifies that PrAG1 is a reproductive gene in *Pinus radiata* and that the PrAG1 promoter is reproductive-tissue specific.

15

Southern blot analysis showed that PrAG1 gene exists as a single copy in the genome of *Pinus radiata* (Figure 4).

## SECTION 2

### **Construction of binary vector pRAGPR, plant transformation and regeneration of transgenic tobacco plants**

20 A DNA fragment containing the PrAG1 promoter (1.46 kb, sequence of Figure 2) operably fused to an RNase gene (0.95 kb, RNS2, Taylor *et al. Proc Natl Acad Sci, USA* 90 (11), 5118-5122 (1993)) and containing Hind III and Sac I sites was gel purified and ligated into the Hind III/Sac I sites of binary vector pRD420, containing the NPTII gene for plant selection, (provided by Dr. R.S.S. Datla, PBI, Saskatoon,  
25 Canada) resulting in the construct pRAGPR (Figure 6). The construct was introduced into *Agrobacterium tumefaciens* (strain c58 MP90), and used to transform and regenerate *Nicotiana tabacum* var. *Xanthi* by the standard leaf disc transformation method (Horsch *et al. (1985), A simple and general method for transferring genes into plants. Science* 227, 1229-1231). Control lines were also  
30 generated through leaf disk method without the selection process. After kanamycin selection, the putative transgenic plantlets were rooted in the rooting medium containing kanamycin and then moved to pots containing the Metromix 350 potting mix. Potted plants were maintained under controlled conditions in a growth chamber with 16h photoperiod. The plants were grown through the full life cycle of



the tobacco until senescence and the flowering of the transgenic tobacco assessed relative to controls. Transgenic plants were identified further by PCR with template of genomic DNA and Southern blot analysis to confirm the integration of pRAGPR in transgenic tobacco plants.

5

#### **Polymerase Chain Reaction Amplification**

To check the genomic DNA integration of pRAGPR in the transgenic tobacco plants, gene-specific primers for the NPTII gene were employed. The primers used were NPTII-5' primer 5-GAA CAA GAT GGA TTG CAC GC-3' (SEQ ID NO. 15) and NPTII-3' primer 5'-GAA GAA CTC GTC AAG AAG GC-3' (SEQ ID NO. 16). Genomic DNA from each of the control lines and transgenic tobacco lines were isolated from the leaf tissue using the Qiagen DNAeasy kit as per manufacturer's instructions. PCR reactions (50- $\mu$ l final volume) were performed using 5  $\mu$ l of template DNA. Samples were heated to 95°C for 4 minutes, followed by 35 cycles of 95°C for 45 seconds, 15 55°C for 30 seconds, and 73°C for 2 minutes, with a final extension step of 73°C for 5 minutes in PTC100 thermal cycler (MJ Research). Amplified DNA fragments were analyzed on a 0.8 agarose gel and visualized by staining with ethidium bromide.

#### **DNA Gel Blot Hybridization**

20 To confirm the genomic integration of PrAG1 promoter-RNase gene cassette in transgenic plants and to determine the copy number, Southern analysis was performed. For Southern analysis, genomic DNA (20 $\mu$ g) was digested with appropriate restriction endonucleases, separated by electrophoresis in a 0.8% agarose gel. Two sets of Southern blots were performed, one with digesting the genomic DNA with Hind III and Sac I to drop the PrAG1-RNase cassette and another with Hind III digest alone to test for integration profiles. Following depurination in 0.25 M HCl and denaturation in 0.5 M NaOH, 1.5 M NaCl, the DNA was blotted onto a nylon membrane. The RNase gene-specific probe (which is the whole RNase gene) was radioactively labelled using a random-primed DECAprime II DNA labeling kit 25 (Ambion, Austin, Texas). Filters were hybridized at 65°C in a hybridization buffer containing 0.5 M NaPO<sub>4</sub> (pH 7.5), 7.5% SDS, and 1mM EDTA. All filters were washed finally at 68°C in 20 mM NaPO<sub>4</sub> (pH 7.5), 1% SDS. Filters were then subjected to autoradiography. 30



containing the pRAGPR construct flowered. The plants with single copy PrAG1-RNase cassette grew at the same rate as controls and senesced at the same time. The transgenic plants with two copies of pRAGPR were slower to grow, and matured late (#1a, 1b and 2).

5

All transgenic plants eventually died and none flowered.

Another phenotypic change observed was in transgenic line #2, which developed additional lateral branches near the top. This may be due to the lack of or decreased apical dominance in these plants. Thus, the inhibition of flowering using the PrAG1-RNase cassette may have an added benefit to increase the biomass of the plant through increased branching if the growing conditions are not limiting.

10

#### INDUSTRIAL APPLICATION

15

In its primary aspect, the invention provides a new, reproductive-tissue-specific promoter. This promoter can be used in transforming a wide variety of plants. The promoter can also be used to drive expression of any gene which it is desirable to express in plant reproductive organs, including flowering time genes.

20

The invention also has application in modulating, and in particular reducing or eliminating reproductive capacity in plants including those of the *Pinus* genus and *Eucalyptus* genus. Such plants have utility in forestry.

25

The availability of reproductively null or sterile pine or eucalyptus trees has the additional advantage that it will be possible to introduce further exogenous genetic material into those trees without the risk that the material will be passed on to other trees.

30

Those persons skilled in the art will appreciate that the specific description provided is exemplary only, and that modifications and variations may be made without departing from the scope of the invention.

**CLAIMS**

1. A polynucleotide which has the nucleotide sequence of SEQ ID NO. 1 and which has the ability, when operatively associated with a nucleotide sequence encoding a peptide, to promote transcription of that nucleotide sequence, or a polynucleotide which is a functionally equivalent variant thereof.
2. A plant reproductive tissue promoter which has the nucleotide sequence of SEQ ID NO. 1 or a functionally equivalent variant thereof.
3. A plant reproductive tissue promoter which has the nucleotide sequence of SEQ ID NO. 2.
4. A DNA construct which comprises:
- (a) a polynucleotide having activity as a transcriptional promoter according to claim 1;
  - (b) an open reading frame polynucleotide coding for a peptide; and
  - (c) a termination sequence.
5. A DNA construct which comprises:
- (a) a promoter sequence according to claim 2 or claim 3;
  - (b) an open reading frame polynucleotide coding for a peptide; and
  - (c) a termination sequence.
6. A construct as claimed in claim 4 or claim 5 in which the open reading frame is in a sense orientation.
7. A construct according to claim 4 or claim 5 in which the open reading frame is an anti-sense orientation.
8. A construct according to any one of claims 4-7 wherein said open reading frame polynucleotide encodes a peptide having SEQ ID NO. 3.

10. A construct according to any one of claims 4-7 wherein said open reading frame polynucleotide encodes a peptide which, when expressed in reproductive tissue of a plant, causes said plant's reproductive organs to redefine themselves as vegetative.

11. A construct according to any one of claims 4-7 wherein said open reading frame polynucleotide encodes a peptide which, when expressed in reproductive tissue of a plant, causes said plant's reproductive organs to stop development.

15 12. A construct according to any one of claims 4-7 wherein said open reading frame polynucleotide encodes a peptide which, when expressed in reproductive tissue of a plant, causes cell death.

13. A construct according to claim 12 wherein the peptide which causes cell  
20 death is selected from diphtheria toxin A and Barnase.

14. A construct according to claim 12 wherein the peptide which causes cell death is an RNase.

25 15. A construct according to claim 14 wherein said RNase is encoded by the  
nucleotide sequence of SEQ ID NO. 5.

16. A construct according to any one of claims 4-7 wherein said open reading frame polynucleotide encodes a peptide, which when expressed in reproductive tissue of a flowering plant, causes an alteration in the timing of flowering of said plant.

17. A construct according to any one of claims 4-16 which further includes:

(d) a selection marker sequence.

18. A construct according to claim 17 in which said selection marker sequence is the NPTII gene.

5

19. A transgenic plant cell which includes a construct according to any one of claims 4-18.

10 20. A transgenic plant which includes a construct according to any one of claims 4-18.

21. A transgenic plant which contains a polynucleotide according to claim 1 or a promoter according to claim 2 or claim 3, which plant has a reduced reproductive capacity.

15

22. A transgenic plant according to claim 21 wherein in said plant said polynucleotide or promoter is operatively associated with a nucleotide sequence encoding a peptide, which when expressed in reproductive tissue of the plant, causes the plant's reproductive organs to abort, redefine as vegetative or stop development.

20

23. A transgenic plant according to claim 21 wherein in said plant said polynucleotide or promoter is operatively associated with a nucleotide sequence encoding a RNase.

25

24. A transgenic plant according to claim 23 in which the RNase has the sequence of SEQ ID NO. 5.

30

25. A transgenic plant according to any one of claims 20-24 wherein said plant is a coniferous plant.

26. A transgenic plant according to claim 25 which is a coniferous plant of the *Pinus* genus.



PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : C07H 21/04, A01H 1/00, C12N 15/82		A1	(11) International Publication Number: WO 00/55172
			(43) International Publication Date: 21 September 2000 (21.09.00)
(21) International Application Number: PCT/NZ00/00031		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 17 March 2000 (17.03.00)			
(30) Priority Data: 334715 17 March 1999 (17.03.99) NZ			
(71) Applicants (for all designated States except US): CARTER HOLT HARVEY LIMITED [NZ/NZ]; 640 Great South Road, Manakau City, Auckland (NZ). TASMAN BIOTECHNOLOGY LIMITED [NZ/NZ]; State Highway 30, Te Teko, Bay of Plenty (NZ). MICHIGAN TECHNOLOGICAL UNIVERSITY [US/US]; 1400 Townsend Drive, Houghton, MI 49931 (US).		<b>Published</b> With international search report.	
(72) Inventors; and			
(75) Inventors/Applicants (for US only): PODILA, Gopi, Krishna [IN/US]; 307 West 42nd Street, Houghton, MI 49931 (US). LIU, Jun-Jun [CN/US]; 900 Champion Street #7, Houghton, MI 49931 (US). KARNOSKY, David, F. [US/US]; Route 1, Box 139, Chassell, MI (US).			
(74) Agents: BENNETT, Michael, Roy et al.; West-Walker Bennett, Mobil on the Park, 157 Lambton Quay, Wellington (NZ).			

(54) Title: PLANTS HAVING MODIFIED REPRODUCTIVE CAPACITY



(57) Abstract

This invention relates to plants having modified reproductive capacity. In particular, it relates to a plant reproductive tissue specific promoter, the PrAG1 promoter isolated from *Pinus radiata*, and its use in promoting transcription/expression of associated genes in plant reproductive tissue, including for the purpose of producing plants which have diminished reproductive capacity or which are sterile.



1/7

[illegible]

**FIGURE 1**

2/7

AAACTCGACAGCAAATATGATTAGATTATGACCTAGAAATAAGCATAGCATTAAAGCAT 60  
ATACATAACAAGCGGTGATATACTCTGACTGCCACTGTACTTGAGGAAAGGTAGTGGACT 120  
CTGCTCAGGTACATTAGTTTGGTAAGGTTGGCTTGGCTTCTGGGTAATATGAGAAGTAAA 180  
GAAGTAAAAGGTATTTGACTCTAGTCAAGTACATTGGATTGCCTTTGTCTGGGGCTTGGAT 240  
GGCTTGGGTTTCGTGTGAGAAGCCAACAATTTATAAGAAATATATAAAATAAAAAATAAAA 300  
AAATTTAAGTGTGGAAGTGAAAACGGTGGGGCAGAAATATACACAGAAGAGTACTTTAA 360  
CAATGCGCAACCAAGGCAGATTCACAACCTTGATTTCTGGACCTCGAATACGAGATAATGG 420  
TGGTAAGAAATAAAGGAAGAGTGGAGTGCATTTGAAAATGAAATGGAGAGCGCACAAAATG 480  
GAGGACGAATAAATGAAATATAATGCAAGAGTGCATTTCCCTATTATTTCCAGAAATGTA 540  
TATGTGGGGTCGGCATTACATGGGCGTCGCATTCAGGGGGTGTCTAGCGGTCCTTTGA 600  
TTGCAGTGTGGGAGTTGCAACATGTACCAACAAATCCATTCAATCCAAAACCTAAATTTA 660  
TCCTCTCCATTACTATTACCTACACCTATACCTAGTAAATATGTCCTGCCTTGTAAGTCC 720  
TCCACTGCCTGCACACGTCTTAGTCAATCCATCTGCCTTCAAATAGGCATTATTTTGTTC 780  
TTTCCCCTCCGACTGAAAGGCTATCGACCGACCGACCGCTCATCTTCTTCTTCTGCGCAA 840  
TTTTTTCTGCTGGATCATCATCATTACCATCATCGCCATCCCCACCATCATCATCATGAT 900  
GGTATCTCTATCTCTCCCTGGCAATCGATTGTAGAGGAAAGGAAGAGGGAAGGGGCATAT 960  
GTATTGATCAACCTACCCGAAAAACAATCTGATCAGCCCTGCTCAATCTTGCTTATAAA 1020  
TCTCTTATCCACTGTTCAATCATTCAGGTTTCTTCCCACTTTCAAGCAAAGGCGCCCGGA 1080  
TTGGCCGTGTTCTTAGATTTTCAGGTACTTAAATGGACAATATTCCCCACCTGAAGCCGT 1140  
TCTGAAAAAGATTTGTTTGTAGAAACAAACGATTGTAATATTTGCTTAAGTTGAGCTTAA 1200  
GGGGTTTGGTACCTAAGTGCCTTGTGGTTATTTGTTTCTCAGAACTCGGGCTGCGTCCA 1260  
ACTGTAGGAACGAACCAGCACAAAGGGGTTGCAGCTTTTGTCTGTTGCTGTTGCGCCCATTG 1320  
CTTTTGGACTGGTATTAGTAGTTGCAGCTTTGTTTTGCATACGCTGTGAGGATCTGTGCG 1380  
CGGAAATTTTGTGTACAAATC 1401

FIGURE 2





FIGURE 3

FIGURE 4



5/7




FIGURE 5




FIGURE 6

7/7

Figure 7




Figure 8





Figure 9



JOINT INVENTORS' DECLARATION FOR PATENT APPLICATION  
AND POWER OF ATTORNEY

As the below named inventors, we hereby declare that:

Our residences, post office addresses and citizenship are as stated below our names.

We believe that we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled: PLANTS HAVING MODIFIED REPRODUCTIVE CAPACITY,

the specification of which:

\_\_\_\_\_ is attached hereto;

  X   was filed on 17 March 2000 as PCT International Application No. PCT/NZ900/00031, was amended on 22 December 2000 and was communicated by the International Bureau.

We hereby authorize our legal representative to add reference to the Serial No. and/or filing date of the above-referenced application to this declaration.

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56.



### Prior Foreign Application(s)

We hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application to which priority is claimed:

Country	Application No.	Date of Filing (day,month,year)	Date of Issue (day,month,year)	Priority Claimed 35 U.S.C.119
New Zealand	334715 /	17 March 1999 /		Yes <u>X</u> No <u>  </u>

### Prior Provisional Application(s)

We hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

Application Serial Number	Date of Filing (day,month,year)
------------------------------	------------------------------------

### Prior U.S. Application(s) and PCT International Application(s) Designating the United States

We hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or § 365(c) of any PCT International application(s) designating the United States listed below:

Application Serial Number	Date of Filing (day,month,year)	Status (Patented, Pending, Abandoned)
------------------------------	------------------------------------	---------------------------------------

Insofar as the subject matter of each of the claims in this application is not disclosed in the prior United States, foreign or PCT International application(s) to which priority has been claimed above in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

We hereby appoint, both jointly and severally, as our attorneys and agents with full power of substitution and revocation, to prosecute this application and any corresponding application filed in the Patent Cooperation Treaty Receiving Office, and to transact all business in the Patent and Trademark Office connected herewith the following attorneys and agents, their registration numbers being listed after their names:


10- Lorance L. Greenlee, Reg. No. 27,894; Ellen P. Winner, Reg. No. 28,547; Sally A. Sullivan, Reg. No. 32,064; Donna M. Ferber, Reg. No. 33,878; G. William VanCleave, Reg. No. 40,213; Susan K. Doughty, Reg. No. 43,595; Heeja Yoo-Warren, Reg. No. 45,495; Tamala R. Jonas, Reg. No. 47,688; Mary Beth Vellequette, Reg. No. 47,903 and Jonathan A. Baker, Reg. No. 49,022 all of Greenlee, Winner and Sullivan, P.C., 5370 Manhattan Circle, Suite 201, Boulder, CO 80303.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

(1) Full Name of

1-00 First Inventor: Gopi Krishna Podila  
 Residence: Houghton, Michigan MI  
 Citizenship: India  
 Post Office Address: 307 West 42<sup>nd</sup> Street  
Houghton, Michigan 49931

(1) Signature




Date: 10/30/01

(2) Full Name of

2-00 Second Inventor: Jun-Jun Liu  
 Residence: Houghton, Michigan MI  
 Citizenship: Canada  
 Post Office Address: 900 Champion Street #7  
Houghton, Michigan 49931

(2) Signature



Date: 11/08/01

(3) Full Name of

Third Inventor:

**David F. Karnosky**

Residence:

Chassell, Michigan MI

**Citizenship:**

**United States of America ✓**

Post Office Address:

**Route 1, Box 139**

## Chassell, Michigan

(3) Signature

Date: 10/26/01